2023 World Conference on Lung Cancer (Posters)-P2.12. Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan

P2.12. Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan - PDF(Slides)

Back to course

Pdf Summary

This document provides a summary of a study conducted in Japan on real-world data of biomarker diagnostics, treatment strategies, and survival outcomes in patients with advanced or recurrent non-small cell lung cancer (NSCLC). The study utilized a large database of approximately 1,500 lung cancer cases.<br /><br />The results of the study showed that half of the patients underwent multi-gene testing, indicating the utilization of precision medicine in the era of biomarker testing. However, the proportion of patients undergoing multi-gene testing was found to be lower than that reported in western countries.<br /><br />The study also found that MET alterations were frequently detected in non-adenocarcinoma, which confirms previous reports. Additionally, the concordance rate between multi-gene testing and single-gene testing was found to be poor for some genes, including ALK.<br /><br />Furthermore, the study examined the overall survival of patients based on different treatment strategies. It was found that patients receiving driver/target therapy had a longer median overall survival compared to patients receiving driver/target therapy- or driver- treatments, which is consistent with previous reports.<br /><br />The document acknowledges the participation of patients and the WJOG Data Center in the study. Overall, this study provides insights into the current status of biomarker testing and treatment outcomes in patients with advanced or recurrent NSCLC in Japan.

Asset Subtitle

Takaaki Tokito

Meta Tag

Speaker Takaaki Tokito

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

biomarker diagnostics

treatment strategies

survival outcomes

non-small cell lung cancer

NSCLC

precision medicine

multi-gene testing

MET alterations

concordance rate

overall survival